文献速递肿瘤 PET/CT骨显像与常规 SPECT核素与放射性配体治疗

骨转移性前列腺癌患者中99mTc-亚甲基二膦酸盐与前列腺特异性膜抗原配体99mTc-MIP-1427的个体内比较

Intraindividual Comparison of 99mTc-Methylene Diphosphonate and Prostate-Specific Membrane Antigen Ligand 99mTc-MIP-1427 in Patients with Osseous Metastasized Prostate Cancer.
PubMed 文献 · J Nucl Med · 2018-01-25

本研究在21例已知晚期骨转移性前列腺癌患者中,于10天内先后进行传统99mTc-MDP骨扫描与PSMA靶向示踪剂99mTc-MIP-1427显像,比较两者对骨转移灶的检出率。结果显示PSMA扫描在多数患者中减少不确定发现,SPECT/CT对区分骨转移与骨外肿瘤病变至关重要。

要点

  • PSMA扫描较骨扫描在16例患者中检出更多可疑病灶
  • SPECT/CT对区分软组织摄取与重叠骨病变至关重要
  • 2例(10%)患者呈现PSMA阴性肿瘤表型

核心结论

  • PSMA扫描通过减少多数患者的不确定发现,较骨扫描具有明显优势。
  • SPECT/CT对区分骨转移与骨外肿瘤病变至关重要。

研究设计与样本

  • 在21例已知晚期骨转移性前列腺癌患者中,于10天内先后进行传统骨扫描与PSMA配体闪烁显像的个体内比较。
  • 显像包括平面全身扫描及SPECT或SPECT/CT(2个床位),分别于注射500-750 MBq的99mTc-MIP-1427或600-750 MBq的99mTc-MDP后3小时进行。
  • 病灶按标准报告方案分为典型肿瘤、不确定(良性/恶性)或正常,并划分解剖区域;采用盲法及共识判读,序贯揭盲:先平面扫描,再SPECT/CT、最佳可评估对照(包括MRI)、PET/CT及随访检查。

主要发现

  • 11例患者有PSMA阳性内脏转移,传统骨扫描可预期未能诊断。
  • 4例患者有广泛的99mTc-MDP阴性骨髓病变。
  • 7例患者骨扫描呈超级骨显像特征,而PSMA扫描上红骨髓受累范围更明显。
  • 仅3例患者骨扫描与PSMA扫描结果等效。
  • 16例患者中PSMA扫描较骨扫描检出更多可疑病灶;2例(10%)患者呈现PSMA阴性肿瘤表型。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The objective of this study was to evaluate the rate of detection of bone metastases obtained with the prostate-specific membrane antigen (PSMA)-targeting tracer 99mTc-MIP-1427, as opposed to conventional bone scanning with 99mTc-methylene diphosphonate (99mTc-MDP), in a collective of patients with known advanced-stage osseous metastasized prostate cancer. Methods: Twenty-one patients with known metastatic disease were staged with both conventional bone scanning and PSMA ligand scintigraphy within a time frame of less than 10 d. Imaging included planar whole-body scanning and SPECT or SPECT/CT with 2 bed positions 3 h after injection of either 500-750 MBq of 99mTc-MIP-1427 or 600-750 MBq of 99mTc-MDP. Lesions were scored as typical tumor, equivocal (benign/malignant), or normal within a standard reporting schema divided into defined anatomic regions. Masked and consensus readings were performed with sequential unmasking: planar scans first, then SPECT/CT, the best evaluable comparator (including MRI), PET/CT, and follow-up examinations. Results: Eleven patients had PSMA-positive visceral metastases that were predictably not diagnosed with conventional bone scanning. However, SPECT/CT was required to distinguish between soft-tissue uptake and overlapping bone. Four patients had extensive 99mTc-MDP-negative bone marrow lesions. Seven patients had superscan characteristics on bone scans; in contrast, the extent of red marrow involvement was more evident on PSMA scans. Only 3 patients had equivalent results on bone scans and PSMA scans. In 16 patients, more suspect lesions were detected with PSMA scanning than with bone scanning. In 2 patients (10%), a PSMA-negative tumor phenotype was present. Conclusion: PSMA scanning provided a clear advantage over bone scanning by reducing the number of equivocal findings in most patients. SPECT/CT was pivotal for differentiating bone metastases from extraosseous tumor lesions.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Rathke H, Afshar-Oromieh A, Giesel FL, et al. Intraindividual Comparison of 99mTc-Methylene Diphosphonate and Prostate-Specific Membrane Antigen Ligand 99mTc-MIP-1427 in Patients with Osseous Metastasized Prostate Cancer. J Nucl Med. 2018. PMID: 29371410. doi:10.2967/jnumed.117.200220

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。